{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:32:16Z","timestamp":1792078336839,"version":"4.4.0"},"reference-count":146,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Discovery"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1080\/17460441.2020.1791078","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T02:46:58Z","timestamp":1594349218000},"page":"1253-1265","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":14,"title":["What is on the horizon for type 2 diabetes pharmacotherapy? \u2013 An overview of the antidiabetic drug development pipeline"],"prefix":"10.1080","volume":"15","author":[{"given":"Karl Sebastian","family":"Johansson","sequence":"first","affiliation":[{"name":"University of Copenhagen","place":["Copenhagen, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Peick","family":"Sonne","sequence":"additional","affiliation":[{"name":"University of Copenhagen","place":["Copenhagen, Denmark"]},{"name":"University of Copenhagen","place":["Hellerup, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip Krag","family":"Knop","sequence":"additional","affiliation":[{"name":"University of Copenhagen","place":["Hellerup, Denmark"]},{"name":"Steno Diabetes Center Copenhagen","place":["Gentofte, Denmark"]},{"name":"University of Copenhagen","place":["Copenhagen, Denmark"]},{"name":"University of Copenhagen","place":["Copenhagen, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkel Bring","family":"Christensen","sequence":"additional","affiliation":[{"name":"University of Copenhagen","place":["Copenhagen, Denmark"]},{"name":"University of Copenhagen","place":["Hellerup, Denmark"]},{"name":"University of Copenhagen","place":["Copenhagen, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,7,9]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107843"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/db16-0806"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62154-6"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2012.11.012"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38678.389583.7C"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60768-0"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-S006"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0066"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-S008"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0413"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2016.01.001"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13042"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.119.257576"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-015-0693-3"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/0145721715607642"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13723"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01337.x"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16008"},{"key":"e_1_3_5_21_1","unstructured":"Pipeline [Internet]. [cited 2020 Jan 27]. Available from: https:\/\/www.novonordisk.com\/research-and-development\/pipeline.html"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2016.16"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S43731"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99114"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2008.06.044"},{"key":"e_1_3_5_26_1","unstructured":"Poxel SA. PXL770 | [Internet]. [cited 2020 Jan 7]. Available from: https:\/\/www.poxelpharma.com\/en_us\/product-pipeline\/pxl770"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2017.09.005"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2017-00016"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2013.08.005"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22344"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1708898"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31785-9"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.25026"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2017.09.029"},{"key":"e_1_3_5_35_1","unstructured":"Viking Therapeutics. Other pipeline programs [Internet]. [cited 2020 Jan 17]. Available from: https:\/\/www.vikingtherapeutics.com\/pipeline\/other-pipeline-programs\/"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-17214-4_12"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2018.05.002"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-s236"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30133-5"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30105-0"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13338"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12474"},{"key":"e_1_3_5_43_1","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of a novel glucokinase activator TMG-123, after multiple oral ascending doses in Japanese type 2 diabetes mellitus patients","author":"Kimura T","year":"2017","unstructured":"Kimura T, Sato H, Shimizu M, et al. Pharmacokinetics, pharmacodynamics, and tolerability of a novel glucokinase activator TMG-123, after multiple oral ascending doses in Japanese type 2 diabetes mellitus patients. Diabetes. 2017;66(Supplement 1):A229-A398.","journal-title":"Diabetes"},{"key":"e_1_3_5_44_1","first-page":"11(475):eaau344","article-title":"Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator","author":"Vella A","year":"2019","unstructured":"Vella A, Freeman JLR, Dunn I, et al. Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator. Sci Transl Med. 2019;11(475):eaau3441.","journal-title":"Sci Transl Med"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2020.1729123"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12452"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01611.x"},{"key":"e_1_3_5_48_1","first-page":"A301","article-title":"Dose-ranging study to determine the optimum dose for imeglimin, a novel treatment for type 2 diabetes","volume":"64","author":"Fouqueray P","year":"2015","unstructured":"Fouqueray P. Dose-ranging study to determine the optimum dose for imeglimin, a novel treatment for type 2 diabetes. DIABETES. 2015;64:A301.","journal-title":"DIABETES"},{"key":"e_1_3_5_49_1","article-title":"Imeglimin monotherapy in Japanese patients with type 2 diabetes: results from a randomised, 24-week, double-blind, placebo-controlled, phase IIb trial","author":"Dubourg J","year":"2017","unstructured":"Dubourg J, Ueki K, Watada H, et al. Imeglimin monotherapy in Japanese patients with type 2 diabetes: results from a randomised, 24-week, double-blind, placebo-controlled, phase IIb trial. Diabetologia. 2017;60(Suppl 1):1-608.","journal-title":"Diabetologia"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0453"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2349"},{"key":"e_1_3_5_52_1","unstructured":"Poxel. Imeglimin - Japan\/Asia [Internet]; 2019 [cited 2019 Jul 9]. Available from: https:\/\/www.poxelpharma.com\/en_us\/product-pipeline\/imeglimin-japan."},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-017-1086-7"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2017.12.021"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.2337\/ds16-0026"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30413-8"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30412-6"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30249-9"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2013.12.001"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32260-8"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13162"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12885"},{"key":"e_1_3_5_63_1","unstructured":"Commissioner O of the. FDA approves first oral GLP-1 treatment for type 2 diabetes. [Internet]. FDA; 2019 [cited 2019 Nov 14]. Available from: http:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-oral-glp-1-treatment-type-2-diabetes"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0749"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1552258"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-2648"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14020"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14032"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2018.01.029"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.2337\/db18-2298-PUB"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.2337\/cd18-0039"},{"key":"e_1_3_5_72_1","unstructured":"ITCA 650 (exenatide implant) [Internet]. Intarcia. [cited 2020 Jan 14]. Available from: https:\/\/www.intarcia.com\/pipeline-technology\/itca-650.html"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1519"},{"key":"e_1_3_5_74_1","unstructured":"Intarcia Announces Successful Cardiovascular Safety Results in Phase 3 FREEDOM-CVO Trial [Internet]. Intarcia; 2016 [cited 2020 Apr 26]. Available from: https:\/\/www.intarcia.com\/media\/media-archive\/press-releases\/intarcia-announces-successful-cardiovascular-safety-results-in-p.html"},{"key":"e_1_3_5_75_1","article-title":"Tolerability, safety, PK\/PD of once-weekly administration of GLP-1 analogue in T2DM patients in china and U.S","author":"Liu Y","year":"2017","unstructured":"Liu Y, Lv Y, Guo X, et al. Tolerability, safety, PK\/PD of once-weekly administration of GLP-1 analogue in T2DM patients in china and U.S. Diabetes. 2017;66(Supplement 1):A229-A398.","journal-title":"Diabetes"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12397"},{"key":"e_1_3_5_77_1","unstructured":"ORMD 0901 - Oral GLP-1 for T2DM. Oramed Pharmaceuticals. [Internet]. [cited 2020 Jan 13]. Available from: https:\/\/www.oramed.com\/pipeline\/ormd-0901\/"},{"key":"e_1_3_5_78_1","first-page":"A326","article-title":"TTP273, oral (nonpeptide) GLP-1R agonist: improved glycemic control without nausea and vomiting in phase 2","volume":"66","author":"Freeman J","year":"2017","unstructured":"Freeman J, Dvergsten C, Dunn I, et al. TTP273, oral (nonpeptide) GLP-1R agonist: improved glycemic control without nausea and vomiting in phase 2. Diabetes. 2017;66:A326.","journal-title":"Diabetes"},{"key":"e_1_3_5_79_1","first-page":"S51","article-title":"Beyond topline results for the oral (non-peptide)GLP-1R agonist TTP273 in type 2 diabetes: how much and when?","volume":"60","author":"Freeman JLR","year":"2017","unstructured":"Freeman JLR, Dunn IM, Valcarce C. Beyond topline results for the oral (non-peptide)GLP-1R agonist TTP273 in type 2 diabetes: how much and when? Diabetologia. 2017;60:S51\u2013S52.","journal-title":"Diabetologia"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30726-8"},{"key":"e_1_3_5_81_1","article-title":"Efficacy, safety, and mechanistic insights of cotadutide a dual receptor glucagon-like peptide-1 and glucagon agonist","author":"Parker VER","unstructured":"Parker VER, Robertson D, Wang T, et al. Efficacy, safety, and mechanistic insights of cotadutide a dual receptor glucagon-like peptide-1 and glucagon agonist. J Clin Endocrinol Metab. 2020;105(3):dgz047.","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_3_5_82_1","unstructured":"Hamni Science [Internet]. [cited 2020 Jan 5]. Available from: http:\/\/www.hanmiscience.co.kr\/science\/handler\/Company-News?seq=90114447&board_id=INFORMATION_COMPANY_NEWS"},{"key":"e_1_3_5_83_1","unstructured":"OPK88003 (Oxyntomodulin Analog) [Internet]. OPKO Health Inc. [cited 2020 Feb 10]. Available from: https:\/\/www.opko.com\/what-we-do\/our-research\/opk88003-oxyntomodulin-analog"},{"key":"e_1_3_5_84_1","unstructured":"Pipeline \u2013 Therapeutic Portfolio. Carmot Therapeutics. [Internet]. [cited 2020 Jan 21]. Available from: https:\/\/carmot-therapeutics.us\/pipeline\/"},{"key":"e_1_3_5_85_1","article-title":"Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens","author":"Frias JP","year":"2020","unstructured":"Frias JP, Nauck MA, Van J, et al. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes Obes Metab. 2020;22(6):938\u2013946.","journal-title":"Diabetes Obes Metab"},{"key":"e_1_3_5_86_1","unstructured":"Pipeline | R&D [Internet]. [cited 2020 Jan 27]. Available from: http:\/\/www.hanmipharm.com\/ehanmi\/handler\/Rnd-Pipeline"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2015.07.092"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci15-0033"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2017.1395020"},{"key":"e_1_3_5_90_1","article-title":"Efficacy and safety of the glucagon receptor antagonist RVT-1502 in type 2 diabetes uncontrolled on metformin monotherapy: A 12-week dose-ranging study","author":"Pettus JH","unstructured":"Pettus JH, D\u2019Alessio D, Frias JP, et al. Efficacy and safety of the glucagon receptor antagonist RVT-1502 in type 2 diabetes uncontrolled on metformin monotherapy: A 12-week dose-ranging study. Diabetes Care. 2020;43(1):161-168.","journal-title":"Diabetes Care"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1343"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-018-1597-1"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13202"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.117.014373"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092494"},{"key":"e_1_3_5_96_1","unstructured":"A study to evaluate the safety tolerability PK and PD of DA-1241 in healthy male subjects and subjects with T2DM [Internet]. [cited 2020 Jan 9]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03646721"},{"key":"e_1_3_5_97_1","unstructured":"CymaBay Pipeline. CymaBay Therapeutics [Internet]. [cited 2020 Jan 9]. Available from: http:\/\/www.cymabay.com\/pipeline.html"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b01198"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-04633-5"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.112.192187"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2020.107555"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2016.12.004"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(00)00305-1"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C117.819110"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4654-7"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-017-0342-8"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4669-0"},{"key":"e_1_3_5_108_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4678-z"},{"key":"e_1_3_5_109_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0166125"},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13645"},{"key":"e_1_3_5_111_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2019.1602116"},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-022577"},{"key":"e_1_3_5_113_1","article-title":"ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASDThe task force for diabetes, pre-diabetes, and cardiovascular diseases of the European society of cardiology (ESC) and the European association for the study of diabetes (EASD)","author":"Cosentino F","year":"2019","unstructured":"Cosentino F, Grant PJ, Aboyans V, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASDThe task force for diabetes, pre-diabetes, and cardiovascular diseases of the European society of cardiology (ESC) and the European association for the study of diabetes (EASD). Eur Heart J. 2019 [Internet]. [cited 2019 Nov 14]. Available from: https:\/\/academic.oup.com\/eurheartj\/advance-article\/doi\/10.1093\/eurheartj\/ehz486\/5556890","journal-title":"Eur Heart J"},{"key":"e_1_3_5_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30165-1"},{"key":"e_1_3_5_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2011.01.001"},{"key":"e_1_3_5_116_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13833"},{"key":"e_1_3_5_117_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13801"},{"key":"e_1_3_5_118_1","unstructured":"Bexagliflozin Efficacy and Safety Trial (BEST) [Internet]. [cited 2020 Jan 22]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02558296"},{"key":"e_1_3_5_119_1","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2013.196"},{"key":"e_1_3_5_120_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-015-0366-7"},{"key":"e_1_3_5_121_1","doi-asserted-by":"publisher","DOI":"10.2337\/db18-114-LB"},{"key":"e_1_3_5_122_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13654"},{"key":"e_1_3_5_123_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22764"},{"key":"e_1_3_5_124_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14248"},{"key":"e_1_3_5_125_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.240820"},{"key":"e_1_3_5_126_1","unstructured":"Lexicon pharmaceuticals announces topline phase 1 clinical results for LX2761 in diabetes [Internet]. [cited 2020 Jan 4]. Available from: http:\/\/www.lexpharma.com\/media-center\/news\/693-lexicon-pharmaceuticals-announces-topline-phase-1-clinical-results-for-lx2761-in-diabetes"},{"key":"e_1_3_5_127_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b01541"},{"key":"e_1_3_5_128_1","unstructured":"Lexicon Pharmaceuticals [Internet]. [cited 2020 Jan 22]. Available from: http:\/\/www.lexpharma.com\/media-center\/news\/733-lexicon-pharmaceuticals-announces-topline-phase-3-data-for-sotagliflozin-in-type-2-diabetes"},{"key":"e_1_3_5_129_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01146-5"},{"key":"e_1_3_5_130_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01517.x"},{"key":"e_1_3_5_131_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.07.027"},{"key":"e_1_3_5_132_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29514"},{"key":"e_1_3_5_133_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2018.1442436"},{"key":"e_1_3_5_134_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31108"},{"key":"e_1_3_5_135_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13425"},{"key":"e_1_3_5_136_1","article-title":"NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis","author":"Harrison SA","unstructured":"Harrison SA, Rossi SJ, Paredes AH, et al. NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis. Hepatology. 2020;71(4):1198-1212.","journal-title":"Hepatology"},{"key":"e_1_3_5_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30474-4"},{"key":"e_1_3_5_138_1","unstructured":"Phase 3 study to evaluate the efficacy and safety of elafibranor versus placebo in patients with nonalcoholic steatohepatitis (NASH) [Internet]. [cited 2020 Feb 5]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02704403"},{"key":"e_1_3_5_139_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.01.038"},{"key":"e_1_3_5_140_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32517-6"},{"key":"e_1_3_5_141_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0618-8278(19)30266-X"},{"key":"e_1_3_5_142_1","unstructured":"FDA. Guidance for Industry Diabetes Mellitus \u2014 Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes [Internet]; 2008 [cited 2019 Jun 28]. Available from: https:\/\/www.fda.gov\/media\/71297\/download"},{"key":"e_1_3_5_143_1","unstructured":"Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus [Internet]; 2012 [cited 2019 Jul 9]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-guideline-clinical-investigation-medicinal-products-treatment-prevention-diabetes-mellitus_en.pdf"},{"key":"e_1_3_5_144_1","unstructured":"Type 2 Diabetes Mellitus: Evaluating the Safety of New Drugs for Improving Glycemic Control; Draft Guidance for Industry; Availability [Internet]. Federal Register; 2020 [cited 2020 Jun 28]. Available from: https:\/\/www.federalregister.gov\/documents\/2020\/03\/10\/2020-04877\/type-2-diabetes-mellitus-evaluating-the-safety-of-new-drugs-for-improving-glycemic-control-draft"},{"key":"e_1_3_5_145_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4677-0"},{"key":"e_1_3_5_146_1","article-title":"The methionine aminopeptidase 2 inhibitor ZGN-1061 improves glucose control and weight in overweight and obese individuals with type 2 diabetes: a randomized placebo-controlled trial","author":"Zafgen Study Group","year":"2020","unstructured":"Zafgen Study Group, JM W, PG C. The methionine aminopeptidase 2 inhibitor ZGN-1061 improves glucose control and weight in overweight and obese individuals with type 2 diabetes: a randomized placebo-controlled trial. Diabetes Obes Metab. 2020;22(7):1215-1219.","journal-title":"Diabetes Obes Metab"},{"key":"e_1_3_5_147_1","doi-asserted-by":"publisher","DOI":"10.2337\/db19-21-OR"},{"key":"e_1_3_5_148_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13021"}],"container-title":["Expert Opinion on Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17460441.2020.1791078","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T16:29:57Z","timestamp":1772728197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17460441.2020.1791078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,9]]},"references-count":146,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1080\/17460441.2020.1791078"],"URL":"https:\/\/doi.org\/10.1080\/17460441.2020.1791078","relation":{},"ISSN":["1746-0441","1746-045X"],"issn-type":[{"value":"1746-0441","type":"print"},{"value":"1746-045X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedc20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedc20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-04-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}